Teilo Schaller, PhD

Program Director, Immune-related Adverse Events

Teilo Schaller joined Project Data Sphere in 2019 as a Program Manager.

Teilo has completed his Ph.D. training at Duke University in the field of Neuro-oncology under the supervision of Professor John Sampson. Prior to that, he received M.Sc. degrees in Biotechnology from ETH Zurich and in Biochemistry from the Technical University of Munich. 

Teilo’s primary interest lies in the discovery, development, and translation of novel cancer therapies. Over the past decade, Teilo has worked on a number of immunotherapies that are in active clinical development, including the bispecific antibody RG7802 (Roche Pharmaceuticals) for the treatment of colorectal cancer, a pp65-dendritic cell vaccine for the treatment of glioblastoma, and two EGFRvIII-targeted bispecific T-cell engagers for the treatment of malignant brain tumors. 

At Project Data Sphere, Teilo is managing programs that will provide researchers with clinical and genomic data to optimize treatment of breast cancer and Merkel cell carcinoma. 

Contact Teilo Schaller, PhD

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.